Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745133 · ClinicalTrials.gov registry record · Phase 4
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
A Phase 4 study of Psoriasis, sponsored by Leon Kircik, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT01745133 is a Phase 4 study of Psoriasis that has completed, run by Leon Kircik, M.D.. The registered enrollment target is 63 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01745133, a Phase 4 study of Psoriasis, has completed, sponsored by Leon Kircik, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis. OLUX-E™ is a medication that contains a corticosteroid delivered in a foam formulation. SORILUX Foam is a foam formulation of calcipotriene. Both medications have been approved by the FDA for treating plaque psoriasis.
Conditions Studied
Interventions
- DRUG vehicle foam
- DRUG calcipotriene
- DRUG calcipotriene + clobetasol propionate
Study Locations (1)
Kentucky
- DermResearch, PLLC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01745133
The ClinicalTrials.gov registry entry for NCT01745133 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (87% lower). The listed sponsor is Leon Kircik, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which vehicle foam is the first listed.
NCT01745133 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT01745133 about?
NCT01745133 is a clinical study titled "Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis". The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis. OLUX-E™ is a medication that contains a corticosteroid delivered in a foam formul...
What is the current status of trial NCT01745133?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2013-01. Estimated completion is 2014-08.
What conditions does trial NCT01745133 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01745133?
The interventions under investigation include: vehicle foam (DRUG), calcipotriene (DRUG), calcipotriene + clobetasol propionate (DRUG).
Who is sponsoring clinical trial NCT01745133?
This trial is sponsored by Leon Kircik, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01745133 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.